Heterogeneity of the aggregation response of human platelets to arginine vasopressin
- 1 May 1995
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 49 (1), 56-66
- https://doi.org/10.1002/ajh.2830490110
Abstract
Previous reports have alluded to variability in the aggregation response of normal human platelets to the neuropeptide arginine vasopressin (AVP). Since it has not been well documented, the current studies were undertaken to characterize this response. AVP (1‐100 nM) produced a concentration‐dependent aggregation response. Although the aggregation response to 100 nM AVP did not correlate with age or sex, there was a bimodal response distribution based on the presence or absence of a second wave of aggregation. In kinetic studies, the apparent km of AVP was 18.3 ± 5.4 nM. There was a significant inverse relationship between the maximal aggregation response to 100 nM AVP and the km (r = −0.82). One hundred nanomolar AVP increased the intracellular calcium concentration of platelets by 406 ± 120 nM in calcium free buffer and by 658 ± 233 nM in the presence of 1.0 nM CaCl2. The aggregation response to 100 nM AVP correlated most strongly with the transmembrane influx of calcium (r = 0.84). In individuals whom 100 nM AVP was able to generate a second wave of aggregation, the selective protein kinase C inhibitor bis‐indolylmaleimide significantly decreased the platelet aggregation response. Thus, there is significant heterogeneity in the aggregation response of normal human platelets to AVP. Based on our kinetic studies and the effects of PKC inhibition on the aggregation response to AVP, we would hypothesize that the variability of the aggregation response of normal human platelets to AVP is related to a polymorphism of the platelet AVP V1 receptor. © 1995 Wlley‐Liss, Inc.Keywords
This publication has 33 references indexed in Scilit:
- Reproducibility and temporal stability of ADP-induced platelet aggregation: Comparison of the anticoagulants sodium citrate and D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketoneAmerican Journal of Hematology, 1991
- Desmopressin-Induced Improvement in Bleeding Times in Chronic Renal Failure Patients Correlates with Platelet Serotonin Uptake and ATP ReleaseThe Lancet Healthy Longevity, 1990
- CHARACTERIZATION OF HUMAN PLATELET VASOPRESSIN RECEPTOR AND THE RELATION BETWEEN VASOPRESSIN‐INDUCED PLATELET AGGREGATION AND VASOPRESSIN BINDING TO PLATELETSClinical Endocrinology, 1988
- Hemoglobin E: An emerging hemoglobinopathy in the United StatesAmerican Journal of Hematology, 1987
- Human platelet fraction arginine-vasopressin. Potential physiological role.Journal of Clinical Investigation, 1987
- HUMAN PLATELET ARGININE VASOPRESSINClinical Endocrinology, 1986
- Effect of heparin on platelet aggregationAmerican Journal of Hematology, 1984
- Vasopressin inhibits the adenylate cyclase activity of human platelet particulate fraction through V1‐receptorsFEBS Letters, 1983
- Human platelet vasopressin receptorsLife Sciences, 1982
- Distribution, blood transport, and degradation of antidiuretic hormone in man.Journal of Clinical Investigation, 1976